{"nctId":"NCT00306163","briefTitle":"Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)","startDateStruct":{"date":"2006-05"},"conditions":["Asthma"],"count":37,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ciclesonide"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fluticasone"]}],"interventions":[{"name":"Ciclesonide","otherNames":[]},{"name":"Fluticasone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* History of bronchial asthma\n* FEV1 \\> 1.20 L\n* Positive Skin Prick Test\n* Not more than 500 mcg/day fluticasone propionate or equivalent for at least 28 days prior to baseline visit\n\nMain Exclusion Criteria:\n\n* Clinically relevant abnormal laboratory values\n* Concomitant severe diseases, diseases expected to interfere with the outcome of the study and diseases which are contra-indications for the use of inhaled steroids\n* Chronic obstructive pulmonary disease (COPD) and /or other relevant lung diseases\n* One asthma exacerbation within 2 months or more than 3 exacerbations within the last year prior to baseline visit\n* Current smokers or ex-smokers with more than 10 pack years, or having smoked within 1 year prior to baseline visit\n* Positive response to saline challenge at baseline visits\n* Positive bronchial hyperresponsiveness","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PC20 AMP (Post-treatment Compared to Baseline)","description":"Mean change of Provocative concentration of Adenosine-5'-monophosphate (PC20 AMP) leading to a 20 percent decrease in Forced expiratory volume in one second (FEV1) between post-treatment and baseline using two different particle sizes. - Small particles = Mass mean aerodynamic diameter (MMAD) of approximately 1.04-1.08 micron - Large particles = MMAD of approximately 9.9-10.6 micron","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"3.7"},{"groupId":"OG001","value":"5.2","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"2.6"},{"groupId":"OG001","value":"3.0","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"2.0"},{"groupId":"OG001","value":"6.0","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"2.3"},{"groupId":"OG001","value":"4.3","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Î” (FVC/SVC) at PC20 (AMP)","description":"Change between baseline and post-treatment of the ratio of Forced Vital Capacity (FVC) and Slow Vital Capacity at PC20. Measured with either small or large partical size AMP.","classes":[]},{"type":"SECONDARY","title":"Safety and Tolerability","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Urticaria","Common cold","Pain armpit","Inflammation of the throat"]}}}